FDA Grants Fast Track Status to Werewolf Therapeutics’ Cancer Drug
WATERTOWN, Mass., October 8, 2025 — Werewolf Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
clinical trials
Advertisement
Eisai Highlights Groundbreaking Oncology Data at ESMO 2025 Congress
NUTLEY, N.J., Oct. 2, 2025 — Eisai Inc. announced today the presentation of its expansive oncology portfolio at the...
FDA Grants RMAT Designation to Avobis Bio’s AVB-114 for Crohn’s Perianal Fistulas
Newark, Del., October 3, 2025 – Avobis Bio LLC, a clinical-stage biotechnology company focused on implantable cell therapies, announced...
Merck Reports Positive HYPERION Results for Pulmonary Hypertension Therapy
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
FDA Fast Track Granted to CS-1103 for Meth Intoxication
CAMBRIDGE, Mass., Sept. 30, 2025 — Clear Scientific, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
FDA Approves Eli Lilly’s Inluriyo for ESR1-Mutated Breast Cancer
Indianapolis, Sept. 25, 2025 – In a landmark advancement for breast cancer treatment, the U.S. Food and Drug Administration...
Tezspire Wins CHMP Backing for Chronic Rhinosinusitis in EU
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
SystImmune Showcases Pivotal ADC Data at ESMO 2025, Strengthening Next-Generation Cancer Pipeline
REDMOND, Wash., Sept. 24, 2025 – SystImmune, Inc. announced the upcoming presentation of new clinical data on izalontamab brengitecan...
FDA Clears Merck’s Keytruda QLEX for Subcutaneous Solid Tumor Use
RAHWAY, N.J. – September 20, 2025 — Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA)...
TREMFYA® Receives FDA Approval for Subcutaneous Induction in UC
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
Advertisement
